| Physiologically‐based pharmacokinetic models for evaluating membrane transporter mediated drug–drug interactions: current capabilities, case studies, future opportunities, and … KS Taskar, V Pilla Reddy, H Burt, MM Posada, M Varma, M Zheng, ... Clinical Pharmacology & Therapeutics 107 (5), 1082-1115, 2020 | 105 | 2020 |
| Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug–drug … G Camenisch, K Umehara Biopharmaceutics & drug disposition 33 (4), 179-194, 2012 | 80 | 2012 |
| Novel In Vitro-In Vivo Extrapolation (IVIVE) Method to Predict Hepatic Organ Clearance in Rat K Umehara, G Camenisch Pharmaceutical research 29, 603-617, 2012 | 80 | 2012 |
| Characterization of human organic cation transporter 1 (OCT1/SLC22A1)-and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4, 9-dioxo-3-(pyrazin-2-ylmethyl)-4 … T Minematsu, M Iwai, K Umehara, T Usui, H Kamimura Drug metabolism and disposition 38 (1), 1-4, 2010 | 71 | 2010 |
| Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations TS Samant, S Dhuria, Y Lu, M Laisney, S Yang, A Grandeury, ... Clinical Pharmacology & Therapeutics 104 (2), 374-383, 2018 | 67 | 2018 |
| Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug–Drug Interaction Potential of Siponimod With Physiologically‐Based Pharmacokinetic Modeling: A … F Huth, A Gardin, K Umehara, H He Clinical Pharmacology & Therapeutics 106 (5), 1113-1124, 2019 | 31 | 2019 |
| The extended clearance model and its use for the interpretation of hepatobiliary elimination data G Camenisch, J Riede, A Kunze, J Huwyler, B Poller, K Umehara ADMET and DMPK 3 (1.), 1-14, 2015 | 30 | 2015 |
| In Vitro to In Vivo Extrapolation of Metabolic Clearance for UGT Substrates Using Short-Term Suspension and Long-Term Co-cultured Human Hepatocytes L Docci, F Klammers, A Ekiciler, B Molitor, K Umehara, I Walter, ... The AAPS journal 22 (6), 131, 2020 | 29 | 2020 |
| Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support … K Umehara, F Huth, Y Jin, H Schiller, V Aslanis, T Heimbach, H He Drug metabolism and personalized therapy 34 (2), 20180042, 2019 | 27 | 2019 |
| Application of the extended clearance classification system (ECCS) in drug discovery and development: selection of appropriate in vitro tools and clearance prediction K Umehara, C Cantrill, MB Wittwer, E Di Lenarda, F Klammers, A Ekiciler, ... Drug Metabolism and Disposition 48 (10), 849-860, 2020 | 26 | 2020 |
| Ribociclib drug‐drug interactions: Clinical evaluations and physiologically‐based pharmacokinetic modeling to guide drug labeling TS Samant, F Huth, K Umehara, H Schiller, SV Dhuria, M Elmeliegy, ... Clinical Pharmacology & Therapeutics 108 (3), 575-585, 2020 | 25 | 2020 |
| Esterase phenotyping in human liver in vitro: specificity of carboxylesterase inhibitors KI Umehara, M Zollinger, E Kigondu, M Witschi, C Juif, F Huth, H Schiller, ... Xenobiotica 46 (10), 862-867, 2016 | 22 | 2016 |
| Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects V Aslanis, K Umehara, F Huth, T Ouatas, S Bharathy, AA Butler, W Zhou, ... Cancer Chemotherapy and Pharmacology 84, 749-757, 2019 | 21 | 2019 |
| Current practices, gap analysis, and proposed workflows for PBPK modeling of cytochrome P450 induction: an industry perspective N Hariparsad, D Ramsden, K Taskar, J Badée, K Venkatakrishnan, ... Clinical Pharmacology & Therapeutics 112 (4), 770-781, 2022 | 20 | 2022 |
| Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction NM Njuguna, K Umehara, F Huth, H Schiller, K Chibale, G Camenisch Drug metabolism and personalized therapy 31 (4), 221-228, 2016 | 19 | 2016 |
| Construction and verification of physiologically based pharmacokinetic models for four drugs majorly cleared by glucuronidation: Lorazepam, oxazepam, naloxone, and zidovudine L Docci, K Umehara, S Krähenbühl, S Fowler, N Parrott The AAPS journal 22, 1-14, 2020 | 18 | 2020 |
| New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data J Riede, B Poller, K Umehara, J Huwyler, G Camenisch European Journal of Pharmaceutical Sciences 86, 96-102, 2016 | 18 | 2016 |
| Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug–drug interaction potential of CYP3A4 substrates K Umehara, F Huth, CS Won, T Heimbach, H He Biopharmaceutics & drug disposition 39 (3), 152-163, 2018 | 17 | 2018 |
| Hepatic uptake and excretion of (–)-N-{2-[(R)-3-(6, 7-dimethoxy-1, 2, 3, 4-tetrahydroisoquinoline-2-carbonyl) piperidino] ethyl}-4-fluorobenzamide (YM758), a novel If channel … K Umehara, M Iwai, Y Adachi, T Iwatsubo, T Usui, H Kamimura Drug metabolism and disposition 36 (6), 1030-1038, 2008 | 15 | 2008 |
| Involvement of CYP2D1 in the metabolism of carteolol by male rat liver microsomes K Umehara, S Kudo, M Odomi Xenobiotica 27 (11), 1121-1129, 1997 | 14 | 1997 |
